logo

For the Inventor, By the Inventor

Novate Milanese, Italy

Matteo D'Anello

This inventor holds 14 USPTO granted patents and 2 published patent applications and 4 EPO patents, primarily in Kinase Inhibitors. Top assignees: Nerviano Medical Sciences S.r.l., Pfizer Italia S.r.l.. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matteo D'Anello. Retrieved from https://idiyas.com/inventor/matteo-d-anello

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14 

% Patents Active = 71.4

 

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 82(Granted Patents)


Location History:

  • Milanese, IT (2012)
  • Milan, IT (2012)
  • Novate Milanese, IT (2009 - 2021)

Company Filing History:

goldMedal8 out of 139 
 
Nerviano Medical Sciences S.r.l.
 patents
silverMedal6 out of 23 
 
Pfizer Italia S.r.l.
 patents

Years Active: 2009-2021

Loading Chart...
Loading Chart...
Areas of Expertise:
Kinase Inhibitors
Pyrrolo Derivatives
Protein Modulation
Phenyl Isoquinolinones
Aminoindazole
Heterobicyclic Pyrazoles
Pyrazino Indoles
Dihydro Pyrazoles
14 patents (USPTO):Explore Patents
1. 11160806 - Salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation, and formulations containing it (2021-11-02),
2. 9422243 - 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors (2016-08-23),
3. 8981092 - Substituted 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-ones as modulators of protein kinase activity (2015-03-17),
4. 8592583 - Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides (2013-11-26),
5. 8513241 - 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them (2013-08-20),
6. 8399668 - Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides (2013-03-19),
7. 8394802 - 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases (2013-03-12),
8. 8207165 - 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them (2012-06-26),
9. 8198298 - Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors (2012-06-12),
10. 8106069 - Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them (2012-01-31),
11. 7888508 - Pyrrolo[2,3-B]pyridine derivatives active as kinase inhibitors (2011-02-15),
12. 7728140 - Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them (2010-06-01),
13. 7511136 - Aminoindazole derivatives active as kinase inhibitors (2009-03-31),
14. 7485661 - Heterobicyclic pyrazole derivatives as kinase inhibitors (2009-02-03),

Title: The Innovative Mind of Matteo D'Anello

Introduction

Matteo D'Anello, an esteemed inventor hailing from Novate Milanese, Italy, has made remarkable contributions to the field of pharmacology and medicinal chemistry. With a portfolio of 14 patents, D'Anello has developed groundbreaking compounds that show promise in treating various medical conditions including cancer and cardiovascular diseases.

Latest Patents

Among his latest innovative patents, Matteo D'Anello introduced a unique salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, along with its preparation and formulations containing it. Additionally, he patented substituted 3-phenyl-isoquinolin-1(2H)-one derivatives as selective PARP-1 inhibitors. These compounds exhibit the capability to selectively inhibit poly(ADP-ribose) polymerase PARP-1, providing significant therapeutic advantages in the treatment of conditions like cancer and central nervous system injuries.

Career Highlights

Matteo D'Anello's career is highlighted by his impactful roles in prominent pharmaceutical companies. He has worked at Nerviano Medical Sciences and Pfizer Italia, where he has collaborated on numerous significant projects that further developed his inventive skills in drug formulation and application.

Collaborations

Throughout his career, D'Anello has collaborated with talented individuals, including coworkers Barbara Salom and Katia Martina. These partnerships have likely fostered an environment of innovation and creativity, further enhancing his contributions to the pharmaceutical industry.

Conclusion

Matteo D'Anello embodies the spirit of innovation, continually pushing the boundaries of science through his inventive mindset. His patents not only demonstrate his expertise but also hold the potential to impact countless lives through the development of new therapeutic strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…